News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Osiris Therapeutics, Inc. (OSIR) Schedules Conference Call to Provide Update on its Grafix┬« Diabetic Foot Ulcer Trial


8/13/2013 6:34:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that C. Randal Mills, Ph.D., President and Chief Executive Officer, will host a conference call to discuss the results of the interim analysis of its multicenter, randomized, controlled trial evaluating the efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers. The call will be held tomorrow, August 13, 2013 at 9:00 a.m. ET.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES